Lipid Droplet-Targeted Biomimetic Liposomes Potentiate Chemo-Ferroptosis Therapy in Leukemia - PubMed
7 hours ago
- #leukemia
- #biomimetic-liposome
- #ferroptosis
- Chemotherapy is the primary treatment for leukemia, but relapse often occurs due to chemoresistant leukemia cells (LCs) in the bone marrow (BM).
- Ferroptosis-based therapies offer a promising strategy to eliminate resistant LCs.
- Cytarabine chemotherapy increases lipid droplet (LD) accumulation in BM-resident LCs, leading to ferroptosis resistance.
- A biomimetic liposome (REM@HLipo) was developed, containing RSL3 (ferroptosis inducer), elacytarabine (cytarabine prodrug), and metformin (LD disruptor).
- Metformin disrupts LDs, increasing polyunsaturated fatty acids (PUFAs) for oxidation, sensitizing LCs to RSL3-induced ferroptosis.
- REM@HLipo shows potent cytotoxicity against BM-resident LCs in AML and ALL mouse models.
- The therapy significantly reduces leukemia stem cell populations in AML models.
- This study introduces a novel chemo-ferroptosis therapeutic approach for leukemia management.